MedPlus Subsidiary Hit by 15-Day Drug License Suspension in Karnataka Leading to Revenue Loss

MedPlus Health Services Ltd. announced on October 11, 2025, that its subsidiary, Optival Health Solutions Pvt. Ltd., has received a 15-day suspension order for the drug license of its store located on MG Road in Chikkamagalur, Karnataka. The suspension, detailed in an exchange filing, is expected to result in a potential revenue loss of Rs 10.15 lakh for the pharmacy chain, adding to its regulatory challenges this year.

This marks the third drug license suspension for MedPlus subsidiaries in 2025. In August, another subsidiary faced a similar order for a store in Maharashtra, while in January, Optival Health Solutions had licenses suspended for two Telangana stores—one in Thorrur Village for three days (Rs 0.45 lakh loss) and another in Kukatpally Bhagyanagar for one day (Rs 2.04 lakh loss). The recurring suspensions highlight ongoing compliance issues for the company across multiple states.

Despite these setbacks, MedPlus shares closed 0.59% higher at Rs 784.20 on the NSE on October 10, outperforming the Nifty index’s 0.41% gain. However, the stock has declined 5.61% year-to-date, though it has risen 18.40% over the past 12 months, reflecting mixed investor sentiment amid operational hurdles.

Also Read: Karnataka Becomes First Major State to Grant Paid Menstrual Leave for All Working Women

The Karnataka suspension underscores the regulatory scrutiny faced by pharmacy retailers in India. As MedPlus navigates these challenges, the company’s ability to address compliance concerns and minimize revenue impacts will be critical to maintaining investor confidence and sustaining its growth trajectory in the competitive healthcare market.

Also Read: Karnataka Schools Closed October 8–18 Teachers Focus on Caste Census